Genetic epidemiology of induced CYP3A4 activity

Pharmacogenetics and Genomics

Volumn 21, Issue 10, 2011, Pages 642-651

  Rahmioglu, Nilufer ^a   Heaton, James ^b   Clement, Gail ^a   Gill, Raj ^a   Surdulescu, Gabriela ^a   Zlobecka, Karolina ^a   Hodgkiss, Dylan ^a   Ma, Yongmin ^b   Hider, Robert C ^b   Smith, Norman W ^b   Ahmadi, Kourosh R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CYP3A4 activity; epidemiology; heritability; induction; twin studies

Indexed keywords

CYTOCHROME P450 3A4;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENETIC EPIDEMIOLOGY; HEREDITY; HERITABILITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; TWINS;

EID: 80052769902     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283498ecf     Document Type: Article

References (33)

1. Hodgson J. ADMET-turning chemicals into drugs. Nat Biotechnol 2001; 19:722-726.
2. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 1957; 165:835-837.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423. (Pubitemid 24229655)
4. Schuetz E . 'Why study the cytochrome P4503A (CYP3A) family?'. In: Daly A, editor. Drug metabolizing enzymes: fundamentals, study methods, recent advances and clinical significance. 2007; London: The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd; 2007.
5. Bode Chris. Dangerous Liaisons, THE SCIENTIST, May 2010, 38-43.
6. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003; 98:175-179. (Pubitemid 36135187)
7. Graham DJ, Green L, Senior JR, Graham DJ, Green L, Senior JR, Nourjah P, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114:299-306. (Pubitemid 36398076)
8. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29:43-44.
9. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's Wort. J Psychopharmacol 2004; 18:262-276. (Pubitemid 38954916)
10. Veronese ML, Gillen LP, Dorval EP, Hauck WW, Waldman SA, Greenberg HA. Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol 2003; 43:1091-1100. (Pubitemid 37174440)
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391. (Pubitemid 32268418)
12. Kanebratt KP, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y, et al. Cytochrome P450 induction by rifampicin in health subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 biomarker 4b-hydroxycholesterol. Clin Pharmacol Ther 2008; 84:589-594.
13. Shelton RC St. John's Wort (Hypericum perforatum) in major depression. J Clin Psychiatry 2009; 70:23-27.
14. Linde K. St. John's Wort-an overview. Forsch Komplementmed 2009; 16:146-155.
15. Roby CA, Anderson GD, Kantor E, Dryer D, Burstein AH. St. John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67:451-457. (Pubitemid 30327483)
16. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294. (Pubitemid 35284253)
17. White NJ, Chanthavanich P, Krishna S, Bunch C, Silamut K. Quinine disposition kinetics. Br J Clin Pharmacol 1983; 16:399-403. (Pubitemid 13015764)
18. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine. Br J Clin Pharmacol Ther 1999; 66:454-460.
19. Mirghani RA, Yasar U, Zheng T, Cook JM, Gustafsson LL, Tybring G, Ericsson O. Enzyme kinetics for the formation of 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. Drug Metab Dispos 2002; 30:1268-1371.
20. Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol 2003; 59:23-28. (Pubitemid 36702755)
21. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73:517-528. (Pubitemid 37249122)
22. Diczfalusy U, Muira J, Roh HK, Mirghani RA, Sayi J, Bertilsson L, et al. 4bhydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008; 18:201-208. (Pubitemid 351323234)
23. Mirghani RA, Ericsson O, Cook J, Yu P, Gustafsson LL. Simultaneous determination of quinine and four metabolites in plasma and urine by highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 754:57-64. (Pubitemid 32241068)
24. Heaton J, Rahmioglu N, Ahmadi KR, Legido-Quigley C, Smith NW. Rapid quantification of quinine and its major metabolite 3-hydroxyquinine in diluted urine by UPLC-MS/MS. J Pharm Biomed 2011; 55:494-499.
25. Kyvik KO. Generalisability and assumption of twin studies. Advances in twin and sib-pair analysis. In: Spector TD, Sneider H, Macgregor AJ, editors. Advances in twin and sib-pair analysis. 2000; London: Greenwich Medical Media; pp. 67-77.
26. Neale MC, Maes HM. Methodology for genetic studies of twins and families. Dordrecht Kluwer Academic Publishers; 1992.
27. Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989; 41:535-552. (Pubitemid 19102462)
28. Kalow W, Endrenyi L, Tang BK. Hypothesis: comparisons of inter and intraindividual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-289. (Pubitemid 28372321)
29. Ozdemir V,Werner K, Bing-Kou T, Paterson AD,Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity drug administration method. Pharmacogenetics 2000; 10:373-388. (Pubitemid 30433571)
30. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4b-hydroxycholesterol in humans. J Biol Chem 2001; 276:38685-38689.
31. Wide K, Larsson H, Bertilsson L, Diczfalusy U. Time course of the increase in 4b-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Parmacol 2008; 65:708-715. (Pubitemid 351535081)
32. Rahmioglu N, Ahmadi KR. Classical twin design in modern pharmacogenomics studies. Pharmacogenomics 2010; 11:215-226.
33. Vormfelde SV, Brockmö ller J, Bauer S, Herchenhein P, Kuon J, Meineke I, et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009; 86:54-61.